Gastroenterology

Oral microbiota therapy rebuilds gut bacteria to prevent recurrent C. difficile infection

VOS, an FDA-approved oral microbiota therapy, has been shown to reduce infection risk compared to traditional fecal transplants. 

Personalized microbiota therapies may be key to treating gut diseases

Effective treatment of IBD requires an approach combining tailored donors, microbiota analysis, and diet.

Bacterial flagella can influence gut health and inflammation

Gut Clostridia can be divided into two groups, with one group contributing to gut inflammation under certain conditions.

IBD and the microbiome: between biological complexity and emerging therapeutic signals

Maurizio Vecchi, gastroenterologist at Policlinico of Milan (Italy), discussed the current and potential role of the microbiome in inflammatory bowel disease (IBD).

Dietary protein could influence cholera infection, mouse study shows

Dietary protein influences V. cholerae growth, metabolism, virulence, and competition with gut microbes.

Postbiotics: the story, the evidences, the ingredient

How postbiotics are reshaping dietary supplements and pharma: key insights from Humiome® Post LB.

Gut microbiota, intestinal barrier, and sepsis: from dysbiosis to probiotics—what preclinical evidence suggests

Francesco Franceschi from Policlinico Universitario A. Gemelli IRCCS (Roma) focuses on bacterial translocation across a compromised intestinal barrier as a plausible pathway contributing to sepsis.

Antibiotic-producing gut microbes might raise infection risk

Lantibiotic-producing gut bacteria can prolong gut imbalance and increase susceptibility to dangerous infections after antibiotics.

Toxin produced by gut bacteria may drive ulcerative colitis

MTB and aerolysin drive gut inflammation in ulcerative colitis.

Microbiome testing for post-infectious IBS: a pilot “microbe-informed” approach presented in Brussels

William Fusco, gastroenterologist at Policlinico Universitario Agostino Gemelli, highlighted a recently published pilot study on post-infectious irritable bowel syndrome (IBS) framed within microbial precision medicine and biomarker-driven care.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.